Previous 10 | Next 10 |
Gainers: Burning Rock Biotech Limited (BNR) +5%. Hemisphere Media Group (HMTV) +4%. Neuronetics (STIM) +4%. AvePoint (AVPT) +3%. Jounce Therapeutics (JNCE) +3%. Losers: UroGen Pharma (URGN) -12%. Purple Innovation (PRPL) -5%. Trinity Capital (TRIN) -4%. ...
There is a lingering sense of optimism about OPK despite shares falling from near $18 to the mid-$3 range. OPK is a great revenue generator with top management but always negative net earnings. There are headwinds, but also some paths for investors to profit if we survive frustrat...
GeneDx Announces Discovery of 200 New and Expanded Genetic Conditions PR Newswire New research underscores the value of sharing genomic information to advance gene matching for diagnosis and discovery GAITHERSBURG, Md. , March 16, 2022 /PRNewswire/ -- ...
COVID-19 test maker, OPKO Health (OPK +7.5%) is trading higher on Tuesday after Chief Executive and Chairman, Dr. Phillip Frost, added more shares into his stake at the company. In a regulatory filing submitted to the Securities and Exchange Commission (SEC) on Monday, Frost disclosed the pur...
Insiders selling Airbnb despite the recent pullback. Co-founder Joe Gebbia significantly increased his selling of Airbnb last week. With the recent pullback in the stock, Airbnb now trades at a trailing EV/sales of 14.11 and a forward EV/sales of 10.66. For further details s...
Saol Therapeutics is collaborating with OPKO Health's (NASDAQ:OPK) unit GeneDx to help in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD) who may be eligible to participate in a Phase 3 clinical trial. The companies said ...
Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease Program Supports Access to A Pivotal Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency (DCA/PDCD trial; NCT02616484) PR Newswire ROSWELL, G...
As the week came to an end, a clutch of investors were ditching Opko Health (NASDAQ: OPK) following the company's Q4 earnings release. Shares of the healthcare diagnostic specialist fell marginally on the day as a result. In the release, published after market hours on Thursday,...
Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q4 2021 Earnings Call Feb 24, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Opko Health (OPK) Q4 2021 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q4 2021 Earnings Conference Call February 24, 2022 04:30 PM ET Company Participants Yvonne Briggs - Investor Relations Phillip Frost - Chairman & Chief Executive Officer Steve Rubin - Executive Vice President Jon Cohen - Managing Director, Executive Chairman of Bio...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common ...
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relat...
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner PR Newswire New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additi...